ORAMED PHARMACEUTICALS INC. Lessee, Operating Lease, Liability, to be Paid, Year One
ORAMED PHARMACEUTICALS INC. (ORMP) had Lessee, Operating Lease, Liability, to be Paid, Year One of $205.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Commitment and Contingencies › Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths · last filed 2026-08-10
- 2026-06-30: Lessee, Operating Lease, Liability, to be Paid, Year One $205.00K.
- 2026-03-31: Lessee, Operating Lease, Liability, to be Paid, Year One $193.00K.
- 2025-12-31: Lessee, Operating Lease, Liability, to be Paid, Year One $192.00K; Lessee, Operating Lease, Liability, to be Paid, Year One as first filed $332.00K.
- 2025-09-30: Lessee, Operating Lease, Liability, to be Paid, Year One $295.00K.
| Period end | Lessee, Operating Lease, Liability, to be Paid, Year One | Lessee, Operating Lease, Liability, to be Paid, Year One as first filed |
|---|---|---|
| 2026-06-30 | $205.00K 10-Q · filed 2026-08-10 | |
| 2026-03-31 | $193.00K 10-Q · filed 2026-05-19 | |
| 2025-12-31 | $192.00K 10-Q · filed 2026-08-10 | $332.00K 10-K · filed 2026-03-26 |
| 2025-09-30 | $295.00K 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $296.00K 10-Q · filed 2025-08-14 | |
| 2025-03-31 | $139.00K 10-Q · filed 2025-05-15 | |
| 2024-12-31 | $141.00K 10-Q · filed 2025-11-13 | $225.00K 10-K · filed 2025-03-27 |
| 2024-09-30 | $221.00K 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $218.00K 10-Q · filed 2024-08-14 | |
| 2024-03-31 | $217.00K 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $222.00K 10-Q · filed 2024-11-07 | $282.00K 10-K · filed 2024-03-06 |
| 2023-09-30 | $267.00K 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $138.00K 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $212.00K 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $291.00K 10-Q · filed 2023-11-09 | |
| 2022-03-31 | $291.00K 10-Q · filed 2023-05-11 | |
| 2021-05-31 | $153.00K 10-Q · filed 2021-07-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |